This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]
Effect of shunt operation on idiopathic normal pressure hydrocephalus patients in reducing caregiver burden: evidence from SINPHONI
Kazui, Hiroaki,
Mori, Etsuro,
Hashimoto, Masaaki,
Ishikawa, Masatsune,
Hirono, Nobutsugu,
Takeda, Masatoshi
Background/aims: Patients with idiopathic normal pressure hydrocephalus (iNPH) are often given shunt operations to reduce the triad symptoms (cognitive impairment, gait disturbance and urinary disturbance). We examined whether they also reduce caregiver burden.; Methods: The personal strain (PS) and role strain (RS) factors, which are related to the stress and constraints, respectively, on the caregivers […]
Long-term effects of group therapy for patients with mild cognitive impairment and their significant others: a 6- to 8-month follow-up study
Banningh, L. W. A. J.-W.,
Roelofs, S. C. F.,
Vernooij-Dassen, M. J. F. J.,
Prins, J. B.,
Rikkert, M. G. M. O.,
Kessels, R. P. C.
The present study examines the long-term effects of a 10-session cognitive behavioural group therapy for patients with mild cognitive impairment (MCI) and their significant others 6 to 8 months after completion of the intervention. Forty-seven MCI patients and 47 significant others participated in the follow-up assessment. Results of the RAND-36, Illness Cognition Questionnaire, IQCODE, GDS-15 […]
Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients? A randomized trial
Joling, Karlijn J,
van Marwijk, Harm W.J.,
Smit, Filip,
van der Horst, Henriëtte E,
Scheltens, Philip,
van de Ven, Peter M.,
Mittelman, Mary S.,
van Hout, Hein P.J.
Background: Family caregivers of dementia patients are at increased risk of developing depression or anxiety. A multi-component program designed to mobilize support of family networks demonstrated effectiveness in decreasing depressive symptoms in caregivers. However, the impact of an intervention consisting solely of family meetings on depression and anxiety has not yet been evaluated. This study […]
The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial
Joling, Karlijn J,
Bosmans, Judith E,
van Marwijk, Harm WJ,
van der Horst, Henriëtte E,
Scheltens, Philip,
Vroomen, Janet L,
van Hout, Hein PJ
Background: Dementia imposes a heavy burden on health and social care systems as well as on family caregivers who provide a substantial portion of the care. Interventions that effectively support caregivers may prevent or delay patient institutionalization and hence be cost-effective. However, evidence about the cost-effectiveness of such interventions is scarce. The aim of this […]
Treatment outcomes of a crisis intervention program for dementia with severe psychiatric complications: the Kansas bridge project
Johnson, D. K.,
Niedens, M.,
Wilson, J. R.,
Swartzendruber, L.,
Yeager, A.,
Jones, K.
Purpose: Although declines in memory and attention are hallmark symptoms of Alzheimer’s disease (AD), noncognitive symptoms are prevalent. Over 80% of individuals will experience neuropsychiatric symptoms, which complicates symptom profiles. Research indicates a community-integrated response to dementia crisis can reduce negative consequences attributed to crisis including increased caregiver burden, increased health care costs, and premature […]
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]